Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Sanofi-aventis Aims at 31 Submissions by the End of 2010
October 22, 2007
-
ARCHIVE DIA Workshop Focuses on Collaborative Clinical Trials in Asia
October 22, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 22, 2007
-
ARCHIVE SymBio Begins PI Study of SyB-0702 in US
October 22, 2007
-
ARCHIVE MediciNova Reports Positive PIIa Results for MN-221 for Status Asthmaticus
October 22, 2007
-
ARCHIVE PMDA Introduces New Training Program to Upgrade Its Reviewers
October 22, 2007
-
ARCHIVE FDA Accelerates Review of Generics to Promote Their Use
October 22, 2007
-
ARCHIVE Korosho to Require Overnight Delivery of Generics
October 22, 2007
-
ARCHIVE Teijin Aims at Share of Over 25% on Market for Osteoporosis Drugs
October 22, 2007
-
ARCHIVE Need to Promote Use of Generics Stressed at JPA Congress
October 22, 2007
-
ARCHIVE Eli Lilly Japan to Price Cialis \100 per Tablet Above Competitors"Prices
October 22, 2007
-
ARCHIVE Lupin of India Acquires Kyowa Pharm. Industry
October 22, 2007
-
ARCHIVE Alcon to Invest US$3 Bil. in R&D over the Next 5 Years
October 22, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 22, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2007
-
ARCHIVE Diovan Keeps Top Position for 5 Consecutive Months
October 22, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 22, 2007
-
ARCHIVE Major Domestic Companies Must Overcome 2010 Crisis
October 22, 2007
-
ARCHIVE Medtronic's Implantable Holter ECG Recommended for Fast-Track Review
October 22, 2007
-
ARCHIVE CFS and Ain Pharmaciez to Merge in April 2008
October 22, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…